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ABSTRACT 
Evidence from economic evaluations is often not used to inform healthcare policy despite being 
well regarded by policymakers and physicians. This article employs the accessibility and 
acceptability framework to review the barriers to using evidence from economic evaluation in 
healthcare policy and the strategies used to overcome these barriers. Economic evaluations are 
often inaccessible to policymakers due to the absence of relevant economic evaluations, the time 
and cost required to conduct and interpret economic evaluations, and lack of expertise to evaluate 
quality and interpret results. Consistently reported factors that limit the translation of findings from 
economic evaluations into healthcare policy include poor quality of research informing economic 
evaluations, assumptions used in economic modelling, conflicts of interest, difficulties in 
transferring resources between sectors, negative attitudes to healthcare rationing, and the absence 
of equity considerations. Strategies to overcome these barriers have been suggested in the literature, 
including training, structured abstract databases, rapid evaluation, reporting checklists for journals, 
and considering factors other than cost effectiveness in economic evaluations, such as equity or 
budget impact. The factors that prevent or encourage decision makers to use evidence from 
economic evaluations have been identified, but the relative importance of these factors to decision 
makers is uncertain. 
 
KEY POINTS FOR DECISION MAKERS 
 Evidence from economic evaluation is used in healthcare decision making if the evidence is 
accessible and acceptable. 
 Accessibility depends on the timeliness of the research, the quality of communication, and the 
decision makers’ level of understanding of economic evidence Acceptability depends on the 
accuracy and validity of research methods, the relevance given institutional structures, and ethical 
concerns. 
 The accessibility and acceptability framework should be used to investigate interventions to 
improve translation of evidence from economic evaluation into policy. Interventions that warrant 
investigation include training decision makers, standardised formats for presenting results, rapid 
evaluation techniques, multi-criteria decision analysis, and awareness raising initiatives. 
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INTRODUCTION 
Rationing by cost effectiveness is regarded by many as necessary to address the high cost of healthcare 
services. Using this approach, funding priority is given to treatments that have the greatest effect at the 
lowest cost [1]. Economic evaluations are often not used in healthcare decision making despite being well 
regarded by policymakers and physicians [2]. This raises the question, what are the barriers to using 
economic evaluations in healthcare decision making and how can these barriers be overcome? 
This narrative overview builds on the work of published reviews of the barriers to using economic 
evaluations [3, 4] by using the accessibility and acceptability framework defined by Williams and Bryan [5]. 
Under this framework, evidence from economic evaluation is used in healthcare decision making if the 
evidence is accessible and acceptable. This framework provides a way to evaluate the trade-offs inherent 
in any strategy to overcome the barriers to using evidence from economic evaluations. There is tension 
between accessibility and acceptability and finding the optimal balance promotes the translation of 
evidence from economic evaluation into practice. 
IDENTIFICATION OF RELEVANT RESEARCH 
This article provides a narrative overview of the barriers to using evidence from economic evaluations in 
healthcare decision-making and strategies used to overcome these barriers. Economic evaluation, 
decision-making, and barrier and facilitator search terms were used to search EMBASE (1947 to 2013). 
Articles were included if they were 1) in English; 2) published as a full article in a peer review journal; and 
3) reported healthcare decision maker attitudes regarding the barriers to using evidence from economic 
evaluations and the strategies to overcome them. The abstracts of the identified papers were screened for 
eligibility. Complete versions of all articles that met eligibility were retrieved.  
Qualitative and quantitative research has been conducted across multiple healthcare settings exploring the 
barriers to using evidence from economic evaluation and the strategies to overcome them [2, 6, 7]. The 
studies were conducted using surveys [2, 8-19], interviews [20-23, 12, 24-30] and focus groups [6, 12, 31], 
and decision making observation [20, 21, 23, 13, 24, 32, 26, 33] of physicians, pharmacists, hospital 
administrators, health technology assessment groups, and politicians.  
ACCESSIBILITY 
An economic evaluation is accessible if the policymaker has timely access to relevant research that is 
understandable [5]. Identified barriers to accessibility include the absence of relevant available economic 
evaluations for decision makers [8, 9, 20, 34, 21-23, 10, 11, 35, 3, 12], the time and cost required to 
conduct economic evaluations [3, 12, 13], decision makers’ lack of time to assess research [14, 24], 
difficulties translating economic evaluations into different contexts [6, 32, 20, 12], and poor awareness of 
current evaluations [8, 24, 34, 6, 3]. Barriers to understanding include poor communication from health 
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economists (including overuse of jargon) [34, 25, 14] complexity of economic evaluation design [26, 20, 
12], excessive variation in economic evaluation methodologies and presentation [3, 8, 25], and lack of 
economic evaluation expertise amongst decision makers [3, 8, 25, 24, 15, 34, 14].  
Decision makers have recommended that health economists should simplify language and analysis 
methods [20, 25, 14] and use standard formats for presenting economic evaluations [3, 25, 34]. Some 
decision makers favour the presentation of results in a disaggregated format (i.e., cost consequence 
analysis) [20, 36]. Attempts have been made to simplify the process of dissemination of evidence from 
economic evaluations, such as the Centre for Reviews and Dissemination (CRD) programme at York 
[37].  
Decision makers from multiple health contexts suggested training as a method of overcoming the barriers 
to using economic evaluations [3, 20, 25, 34]. As far as the authors are aware, there are no studies in the 
academic literature that have assessed the impact of training on decision makers’ attitudes and knowledge 
of economic evaluation. Training material was provided in the pilot study conducted by Claxton et al. [31] 
to investigate the potential for decision analysis and value for information analysis to inform the 
prioritisation process of the National Health Service’s Health Technology Assessment (HTA) 
programme. Some members of the HTA programme said that the training material was insufficiently 
detailed, while others said that the material was too detailed and technical.  
Hoffmann et al. [6] conducted focus group research with decision makers to evaluate whether they found 
the National Health Service Economic Evaluation Database (NHS EED) facilitated the accessibility of 
evidence from economic evaluations. The NHS EED contains structured abstracts of published 
economic evaluations, and was designed to overcome accessibility barriers. The decision makers in the 
focus group reacted positively to the NHS EED, saying that it would aid in the identification of relevant 
research. The decision makers identified limitations of the NHS EED including the lack of 
generalizability the evaluations in the database conducted outside of the UK and the inability to evaluate 
the quality of the evidence from the economic evaluation given the compressed format of the NHS EED 
study summaries.  
ACCEPTABILITY 
Just because healthcare decision makers can use evidence from economic evaluations does not mean that 
they would want to. A decision maker might not want to use an economic evaluation because it lacks 
scientific, institutional, or ethical acceptability [5].  
Scientific acceptability 
Evidence from economic evaluation is scientifically acceptable if the methods are valid and the results are 
unbiased [5]. Decision makers have reported concerns about some of the methods used in economic 
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evaluations. Such methodological issues include poor quality of research informing economic evaluations 
[26, 25, 6, 12], use of quality adjusted life years (QALYs) to measure health effects [3, 27, 25], methods 
used to estimate indirect and overhead costs [28, 12], economic modelling assumptions [26, 25, 34, 12], 
and the appropriateness of the cost effectiveness threshold [3, 26, 9, 20, 12]. There are a number of 
published guidelines that provide recommendations to increase the methodological validity and 
consistency of economic evaluations [38, 39]. These guidelines allow flexibility of methods such that 
health economists can use their judgement to develop the best and most feasible models for a given 
clinical question and context.  
Decision makers regard conflicts of interest as a barrier to using economic evaluations [3, 20, 25, 33]. 
Industry sponsored economic evaluations are prevalent in the academic literature [40], raising concerns 
that methods are being selected that introduce bias, whether in the model design or the selection of 
parameters. Economic evaluations are susceptible to publication bias, as economic evaluations with 
positive findings are more likely to be published [41].  
Another aspect of scientific acceptability is whether economic evaluation is consistent with welfare 
economics and economic principles more generally. Although the consistency of economic evaluation 
with welfare economics has been debated in the academic literature [42, 43], it was not a concern to the 
decision makers surveyed or interviewed about the barriers to using economic evaluations [3, 4]. None of 
the decision makers in the literature reported lack of adherence to economic principles, such as Kaldor 
Hicks efficiency, as a barrier to using evaluations to inform healthcare decisions or policy. 
Institutional acceptability 
Evidence from economic evaluation is institutionally acceptable when it meets the institutional needs of 
the decision maker. Policymakers and healthcare practitioners have recommended that health economists 
need to demonstrate better understanding of the decision making process, particularly with regard to the 
difficulties in transferring resources between sectors and adjusting budgets for new therapies [3, 20, 34, 
29, 12]. Decision makers have found that published economic evaluations often address a narrow scope 
of research questions and typically ignore concerns that decision makers face, such as human resource 
management decisions [24, 6]. Conversely, economic evaluations of nationwide programs can be too 
broad to be of relevance to individual hospitals who have specific requirements and timeframes [3]. 
Following guidance from an economic evaluation might not be institutionally acceptable if it advocates 
disinvestment of an established technology [3, 16], or if the findings run contra to the short-term focus of 
decision makers [17, 18]. Decision makers have found that potential economic benefits of interventions 
highlighted in economic evaluations are not being realized in practice [3, 20, 34].  
Approaches that that have been suggested to improve the institutional acceptability of economic 
evaluations include making economic evaluations more relevant to the decision making context [3, 22], 
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allowing flexibility in decision making budgets to adopt recommended changes [2], incorporating budget 
and resource reallocation constraints in economic models [44, 30], making economic evaluations more 
sensitive to questions that healthcare decision makers need answers to [3, 22], involving all stakeholders in 
the economic evaluation process [22], and demonstrating direct benefit to the administrator or 
department [14]. Official requirement to demonstrate the cost effectiveness of interventions for third 
party funding or reimbursement also promotes the development and use of economic evaluations [19]. 
The impact of economic evaluations on policy is related to the level of cooperation between researchers 
and policy makers [3, 33], which explains why the economic evaluations most successful in influencing 
policy are those that are commissioned by the policy makers themselves [45-47]. 
Ethical acceptability 
Ethical acceptability refers to whether the decision maker and the wider community consider the 
methods, findings or recommendations from the research to be ethically “right”. A concern that has been 
raised by decision makers is that economic evaluations rarely analyze the impact that an intervention has 
on equity [3, 16, 48, 49, 25]. There are many ways to address equity concerns depending on the equity 
criteria of the decision makers [50]. If policymakers want to know the impact of a policy on equality in 
health outcomes or access to services then health economists should try to find an effective way to 
present this information. 
Explicit rationing itself is ethically unacceptable to some decision makers [51]. There can be conflict 
between the individual ethic of the doctor patient relationship and the population ethic of cost 
effectiveness [3, 28]. The doctor patient relationship centres on the effectiveness and safety of treatment, 
with less concern about the cost of treatment. But economic evaluations take a social or administrative 
perspective, where between-patient trade-offs in the use of healthcare resources need to be accounted for. 
This can result in economic evaluation becoming synonymous with cost cutting in the eyes of doctors 
[35, 3, 22]. To address this concern, economic evaluations should highlight to doctors and other health 
professionals the benefits accrued to all their patients as opposed to any one patient.   
ACCESSIBILITY AND ACCEPTABILITY TRADE-OFFS 
The concepts of accessibility and acceptability provide a framework to evaluate strategies to increase the 
usefulness of evidence from economic evaluations or increase the impact that the evidence has on policy. 
These strategies can have different effects on each of components of accessibility and acceptability. The 
nature of these interactions have not been assessed empirically, but some interactions can be speculated 
(Table 1). 
Such interactions can be tradeoffs. Sophisticated statistical techniques might improve scientific 
acceptability but make the research less accessible due to increased time to conduct analysis and difficulty 
in understanding results. Rapid evaluation methods sacrifice scientific acceptability to improve 
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accessibility [52, 53]. Decision makers might find it easier to understand disaggregated results of economic 
evaluations rather than, say, an incremental cost effectiveness ratio, but this approach provides less 
support for a scientifically rigorous decision. Industry sponsorship may have a negative impact on 
perceptions of scientific acceptability, but without industry sponsorship many economic evaluations 
would not be conducted, limiting accessibility. Involving community members in healthcare priority 
decisions might improve community attitudes to economic evaluation and healthcare rationing, but their 
recommendations might not sit well with institutional powerbrokers. Incorporating budget and equity 
constraints into an economic evaluation might improve institutional and ethical acceptability but also 
takes time, adds complexity, and opens the door for criticism of methods.  
Writing well improves understanding, but at a cost [54]. It takes time to write clearly and 
comprehensively. Writing well requires experience, thoughtfulness, and repeated edits. Technical language 
is a barrier to understanding for non-specialists, but researchers need to demonstrate their understanding 
of technical language to gain academic credibility. Poor writing might even be a rational response to the 
incentives researchers face [55, 56]. 
Decision makers may like to see economic evaluations consider budget impact, resource constraints and 
equity impact, but adding these factors contributes to the complexity of the economic evaluation. Each of 
these factors introduces new concepts that the reader has to grasp. They each demand knowledge and 
effort from the researcher to be calculated credibly [57, 58].  
If cost effectiveness, budget impact, resource constraints, and equity impact are all reported, another level 
of complexity is introduced because these criteria need to be weighed up to make a decision. Multi-criteria 
decision analysis can be used to make this approach explicit. A multi-criteria decision analysis instrument 
allows for the trade-off between criteria in a way that facilitates the rank ordering of a set of interventions 
[59]. But multi-criteria decision analysis introduces more concepts to be understood and it requires time 
to develop such a decision tool. 
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Table 1 Potential accessibility and acceptability interactions 
 Accessibility Acceptability 
Strategy Availability Understandability Scientific Institutional Ethical 
Rapid evaluation techniques 
 
     
Use plain language 
 
     
Disaggregated presentation of results (cost 
consequences analysis) 
     
Complex modelling techniques to 
minimize bias 
     
Conducting economic evaluations with 
industry sponsorship 
     
Conducting economic evaluations 
independent from industry sponsorship 
     
Clearly stating assumptions and data 
sources 
     
Incorporating budget and resource 
reallocation constraints  
     
Involving community members in 
healthcare priority decisions 
     
Multi-criteria decision analysis to 
incorporate equity concerns 
     
 
DISCUSSION 
There is tension between the academic rigour of health economics and the realities of policymaking 
making. The incentives that health economists face are misaligned with those of policymakers. Health 
economists gain prestige by publishing in academic journals and using complex methods that demonstrate 
technical competence. This puts priority on scientific acceptability; making sure the methods are valid and 
the results unbiased. But the healthcare decision makers who are in the position to use evidence from 
economic evaluations care about more than scientific acceptability.   
The evidence needs to be promptly available, understandable, institutionally appropriate, and ethical. 
There is a short window of opportunity for evidence from economic evaluations to have an impact on 
healthcare decision making. Healthcare decision makers rarely have much experience interpreting 
economic evaluations. Each healthcare setting has its own institutional needs and ethical norms. 
Economic evaluations produced for healthcare decision making are often simpler and less rigorous than 
evaluations published in academic journals [3].  
Each of the barriers to using economic evaluation prompts a potential strategy to solve the problem. But 
the solution to one barrier can exacerbate another. Sophisticated mathematical and statistical techniques 
can improve the accuracy of cost effectiveness estimates but are difficult to understand. Industry 
sponsorship of economic evaluations leads to more evaluations being published, which increases 
accessibility, but also lead to concerns about bias. In each case there is a trade-off between factors. 
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The factors that prevent or encourage decision makers to use evidence from economic evaluations have 
been identified, but the relative importance of these factors to decision makers is uncertain. Without a 
gauge for this relative importance one cannot determine whether sacrificing acceptability for accessibility 
is worthwhile. This relative importance is likely to depend on the nature of the decision and decision 
makers. It would be valuable to quantify the relative importance of factors that prevent or encourage the 
use of evidence from economic evaluation in healthcare decision making across multiple settings. 
There is a distinction between the acceptability of economic evaluations as published and the acceptability 
of concepts used in economic evaluations. Even when evidence from economic evaluations does not 
change policy decisions, notions of costs and benefits have become pervasive [24]. Decision makers 
might not be using formal economic evaluations to inform decision making, but they still use concepts of 
efficiency and opportunity costs in decision making.  
To increase the impact of economic evaluation on policy, health economists need to engage with 
policymakers, healthcare professionals, and the community. Health economists should lead the discussion 
of the importance of eliminating wasteful health spending. Health economists need to be free of financial 
conflicts of interest to make this case credibly.  
CONCLUSIONS 
Economic evaluations cannot improve the quality of healthcare unless research translates into policy, so it 
is crucial to understand the barriers to using economic evaluation for healthcare decision making and the 
strategies to overcome these barriers. It is not sufficient for an economic evaluation to be accessible to 
decision makers, it must also be acceptable. 
The accessibility and acceptability framework provides not just a way to understand the barriers to using 
economic evaluation but also a way to evaluate proposed strategies to encourage the use of economic 
evaluations. This paper predicts effects that these strategies will have on acceptability and accessibility but 
these predictions are yet to be confirmed empirically. Interventions that warrant investigation under this 
framework include training decision makers to be able to interpret economic evaluations, standardized 
formats for presenting results of economic evaluations, rapid evaluation techniques, multi-criteria 
decision analysis to incorporate concerns other than cost effectiveness, and awareness raising initiatives. 
We know what stops healthcare policymakers from considering economic evidence, the next step is to 
formulate opportunities to encourage them to start using the evidence.   
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